CombinatoRx Declares Positive Results For AR Synavive

CombinatoRx has declared positive results from a Phase-I clinical study, evaluating the relative bioavailability of an oral once-daily aligned-release (AR) formulation of Synavive.

The pharmacokinetic profiles observed in this study suggested that a once-daily Synavive AR formulation may provide similar exposure and improved tolerability in comparison to the twice-daily (BID) formulation of Synavive used in Phase 2 studies to-date. Synavive was well-tolerated and there were no study drug-related serious adverse events reported.

Alexis Borisy, President and CEO of CombinatoRx, said: “By aligning the release profiles of prednisolone and dipyridamole in an oral, once-daily formulation, we have successfully achieved our goal of maintaining the synergistic activity of the combination to potentially retain efficacy and improve tolerability.”

“Having achieved this goal, Synavive with its demonstrated activity in Phase 2 osteoarthritis and rheumatoid arthritis clinical trials, could be an exciting product opportunity going forward,” he added.